KMDA Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

8.580

Open

8.575

VWAP

9.00

Vol

7.00K

Mkt Cap

498.00M

Low

8.575

Amount

64.00K

EV/EBITDA(TTM)

10.00

Total Shares

58.00M

EV

438.00M

EV/OCF(TTM)

15.00

P/S(TTM)

3.00

Kamada Ltd is Israel based company, focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.

Show More

Events Timeline

(ET)

2026-01-07

07:10:00

Kamada Forecasts 2026 Revenue of $200M to $205M

2025-12-18 (ET)

2025-12-18

12:10:00

Major Averages Rise as CPI Report Released

2025-12-18

07:20:00

Kamada Reiterates 2025 Revenue Guidance of $178M to $182M

2025-12-18

07:20:00

Kamada Awarded $10M-$14M Contract Extension from Canadian Blood Services

2025-12-08 (ET)

2025-12-08

16:20:00

Major Averages Decline as Markets Await Fed Rate Decision

2025-12-08

12:00:00

Major Averages Lower as Markets Await Fed Rate Decision

2025-12-08

07:10:00

Kamada Discontinues Phase 3 Trial for Alpha-1 Antitrypsin Deficiency

2025-12-08

07:10:00

AATD Reiterates 2025 Revenue Guidance of $178M to $182M

2025-11-10 (ET)

2025-11-10

07:10:23

Kamada projects FY25 revenue between $178 million and $182 million.

News

an image of Barron's

Analyst Predicts Increase in Hubspot Stock, Along with Insights on McGraw Hill, UHS, and Other Stocks.

an image of Globenewswire

01-07Globenewswire

Kamada Forecasts $200M-$205M Revenue for 2026 with 13% Growth

an image of Globenewswire

2025-12-18Globenewswire

Kamada Secures Supply Tender Extension, Ensuring $5-$7 Million Annual Sales

an image of Newsfilter

2025-12-18Newsfilter

Kamada Secures Supply Tender Extension from CBS, Ensuring $5-$7 Million Annual Sales

an image of Benzinga

2025-12-08Benzinga

Kamada Halts Phase 3 Trial for Genetic Disorder, Reaffirms Future Projections

an image of Globenewswire

2025-12-08Globenewswire

Kamada Discontinues AAT Trial After Futility Analysis, Reiterates 2025 Revenue Guidance of $178M-$182M

2 Analyst Rating

Wall Street analysts forecast KMDA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KMDA is 14.00 USD with a low forecast of 13.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

13.00

Averages

14.00

High

15.00

Current: 0.000

Low

13.00

Averages

14.00

High

15.00

H.C. Wainwright

Buy

maintain

$11 -> $13

AI Analysis

2025-12-09

Reason

H.C. Wainwright

Price Target

$11 -> $13

AI Analysis

2025-12-09

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on Kamada to $13 from $11 and keeps a Buy rating on the shares. The company decided to discontinue its Phase 3 inhaled alpha-1 antitrypsin deficiency clinical trial based on the results of the planned interim futility analysis, the analyst tells investors in a research note. The firm says the decision helps to refocus the company on its core products and eliminates a "long over-hanging distraction that was unlikely to be fruitful."

Benchmark

Robert Wasserman

Strong Buy

Initiates

$15

2025-03-21

Reason

Benchmark

Robert Wasserman

Price Target

$15

2025-03-21

Initiates

Strong Buy

Reason

Benchmark analyst Robert Wasserman initiated coverage of Kamada with a Buy rating and $15 price target.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for KMDA

Unlock Now

Valuation Metrics

The current forward P/E ratio for Kamada Ltd (KMDA.O) is 16.25, compared to its 5-year average forward P/E of 4.23. For a more detailed relative valuation and DCF analysis to assess Kamada Ltd 's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

an image of dotted line Image

N/A

5Y Average PE

4.23

Current PE

16.25

Overvalued PE

12.77

Undervalued PE

-4.31

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

an image of dotted line Image

5Y Average EV/EBITDA

5.38

Current EV/EBITDA

6.83

Overvalued EV/EBITDA

10.02

Undervalued EV/EBITDA

0.73

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

an image of dotted line Image

5Y Average PS

2.08

Current PS

2.09

Overvalued PS

2.65

Undervalued PS

1.50

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

Intellectia · 36 candidates

Market Cap: 300.00M - 1.00BPrice: $5.00 - $20.00Quarter Revenue Yoy Growth: >= 5.0%Pe Ttm: 8 - 25Monthly Average Dollar Volume: >= 500,000

Ticker

Name

Market Cap$

Radiant Logistics Inc

304.00M

Hudson Technologies Inc

309.00M

Waterstone Financial Inc

323.00M

Nexxen International Ltd

369.00M

Ponce Financial Group Inc

374.00M

Colony Bankcorp Inc

394.00M

Whales Holding KMDA

Phoenix Investments & Finances Ltd

Trading Trends

People Also Watch

Frequently Asked Questions

What is Kamada Ltd (KMDA) stock price today?

The current price of KMDA is 8.61 USD — it has decreased -0.35 % in the last trading day.

What is Kamada Ltd (KMDA)'s business?

Kamada Ltd is Israel based company, focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.

What is the price predicton of KMDA Stock?

Wall Street analysts forecast KMDA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KMDA is14.00 USD with a low forecast of 13.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Kamada Ltd (KMDA)'s revenue for the last quarter?

Kamada Ltd revenue for the last quarter amounts to 47.00M USD, increased 12.63 % YoY.

What is Kamada Ltd (KMDA)'s earnings per share (EPS) for the last quarter?

Kamada Ltd. EPS for the last quarter amounts to 0.09 USD, increased 28.57 % YoY.

How many employees does Kamada Ltd (KMDA). have?

Kamada Ltd (KMDA) has 374 emplpoyees as of January 29 2026.

What is Kamada Ltd (KMDA) market cap?

Today KMDA has the market capitalization of 498.00M USD.